Annovis partners with NeuroRPM on Parkinson’s study
Annovis has announced a strategic partnership with NeuroRPM to integrate an FDA 510(k)-cleared AI platform into its open-label ANVS-25002 study on Parkinson’s disease. This study, which is currently enrolling participants at 25 sites across the U.S., aims to evaluate the efficacy of buntanetap over a 36-month period. The NeuroRPM system will continuously capture movement data to monitor core motor symptoms such as bradykinesia, tremor, and dyskinesia, generating real-time digital biomarkers of symptom changes.
This innovative approach combines digital and biological biomarkers, enhancing precision in assessing treatment responses and disease progression. Annovis is also incorporating a skin-based assay for misfolded phosphorylated alpha-synuclein, which boasts over 90% diagnostic sensitivity and specificity. With 90 of the projected 500 patients already enrolled, this study could set a new standard for monitoring Parkinson’s disease, potentially allowing participants to continue using the NeuroRPM technology post-study for ongoing clinical assessment.
The integration of AI-driven monitoring with robust biological assays represents a significant step toward personalized medicine in neurodegenerative diseases, potentially transforming how treatment efficacy is evaluated.